ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

ZoeNCure Therapeutics Pvt. Ltd., an oncology biotechnology firm dedicated to the development of targeted cancer therapies, has successfully concluded a Seed funding round amounting to INR 20 Crore. This investment is equivalent to approximately $2.4 million USD and was primarily led by the Tyagi Family, a group of high-net-worth individuals from Gurugram, India, including Mr. [...] The post ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program appeared first on The CSR Journal .